Thromboxane A2 (TxA2) receptors in human eye sections were identified and localised using a potent TxA2 specific agonist, "15-iodinated 5-heptenoic acid 7-[3-[3-hydroxy-4-[4-(iodo-"51I) (BrJ7 Ophthalmol 1994; 78: 921-926) 
Thromboxane A2 (TxA2) is a potent vasoconstrictor and platelet aggregating agent which is thought to be involved in the pathophysiology of cardiovascular disease' and some circulatory disorders2-4 such as thrombosis, atherosclerosis, angina, coronary artery vasospasm, and acute myocardial infarction. In the eye, it has been reported that TxA2 plays a role in ocular traumatic reactions,5 ocular inflammation,6 and in the pathophysiology of cystic macular oedema (CMO).7 Although the precise mechanism of action in these situations is still not fully elucidated, it is believed that these activities are receptor mediated. 8 Because both TxA2 and its precursor, prostaglandin H2, show similar pharmacological properties, they are presumed to share a common receptor, which has been named the TxA2/PGH2 or TxA2 receptor. The existence of TxA2 receptors in platelets is extensively substantiated by a variety of radioligand binding studies and platelet aggregation bioassays."5 The evidence for putative receptors in smooth muscle derives mainly from studies of smooth muscle constriction in tissues including dog saphenous vein, rabbit aorta, and guineapig trachea. '6 There are also physiological studies evaluating the functions of TxA2 in smooth muscle from different organs such as guineapig lung, ileum, fundic strip, trachea, rat stomach, and also in cat and dog iris sphincter muscle strips. ' 
Results
Representative autoradiograms illustrating the distribution of '25I-BOP binding sites in the human eye are shown in Figure 1 . Quantitative densitometric analyses showed that the highest densities of specific binding sites were located in the corneal epithelium, in the ciliary processes, in blood vessels surrounding the optic nerve, and in the retina (Table 1 , Fig IA) . The density of binding was reduced dramatically in the presence of 1 FtM non-radioactive BOP (Fig 1B) , SQ27427 (Fig 1C) , and U46619 (data not shown), indicating that specific labelling occurred in these structures. Although both the lens I-.r and choroid showed moderate levels of signal, these were not displaceable and not significantly higher than those of the corresponding nonspecific binding levels shown in Figure IC . In situ hybridisation investigations of the localisation of mRNAs coding for TxA2 receptors were broadly consistent with the results obtained from the ligand binding assays (Fig 2A) . Within the anterior segment, the highest density of hybridisation sites were found in the corneal epithelium and in the ciliary processes. Although hybridisation to blood vessels was not detected in the posterior segment of the eye, a high density of reaction product was seen in the retina. Figure 3 illustrates the results of liquid emulsion autoradiography using '25I-BOP as a ligand. The results at low power (not shown) were the same as those illustrated in Figure 1 . The high magnification views of Figure 3 show that the ciliary process binding sites identified at low power in Figure 1 were concentrated on nonpigmented epithelial cells within the processes rather than on pigmented cells (Fig 3A, B) . For the blood vessels at the optic nerve head, emulsion autoradiography showed that the binding was concentrated on the endothelial cells of the ciliary artery rather than on nearby smooth muscle cells (Fig 3C, D) , and within the retina a high density of binding sites were seen only within the photoreceptor layer (Fig 3E, F) .
Discussion
The localisation of TxA2 receptors has been examined in human eye sections using film autoradiography, liquid emulsion autoradiography, and in situ hybridisation techniques. The results from the three different methods are similar, consistent, and complementary to each other.
In the autoradiographic binding studies, the In the retina only the photoreceptor layer is labelled (F) and the ganglion cell layer, bipolar cell layer, and inner or outer plexiform layers illustrated in (E) 28 They demonstrated the existence of TxA2 receptors in hypertensive membrane preparations of bovine pulmonary artery endothelial cells using a ligand binding assay with a potent TxA2 specific antagonist, '25I-PTA-OH. They found that U-46619 suppressed prostacyclin-PGI2 (the most potent vasodilator and platelet inhibitor) production in cultured endothelial cells. Furthermore, the suppression of PGI2 by U-46619 could be blocked by the TxA2 specific antagonists, I-PTA-OH or SQ29 548. Thus, it has been hypothesised that the vasoconstriction effect of TxA2 may be caused by suppressing the release of vasodilators from vascular endothelial cells, resulting in an enhanced vasoconstriction of blood vessels. Our results indicating TxA2 receptor binding in endothelial cells of posterior ciliary artery support this hypothesis and may also help us to understand the pathological mechanism of glaucomatous optic neuropathy. Further studies in glaucomatous eyes with a focus on the optic nerve head and associated blood vessels are required to address the question ofwhether there are any changes in the TxA2 receptor binding sites in glaucomatous eyes.
Compared with classic prostaglandins, the binding sites for the TxA2 receptor in the anterior segment were mainly located on nonpigmented epithelial cells ofthe ciliary processes, whereas PGE2 and F2a binding is mostly concentrated within the ciliary muscle. 29 The non-pigmented epithelial cells of the ciliary processes are not only acting in aqueous humour production but are also involved in the maintenance of the blood-aqueous barrier (BAB). Although PGE2 induces most of the features of ocular inflammation, it has been found that levels of TxB2 (the metabolic product of TxA2) are significantly increased in vitamin E unsupplemented uveoretinitic rats. 30 The role of TxA2 in the conjunctiva and alkaline burn reaction of the eye has also been examined since changes in the aqueous humour production and the breakdown of BAB are used extensively to indicate intraocular inflammatory reactions. The existence of TxA2 receptors in non-pigmented epithelial cells of the ciliary processes implies a possible role of TxA2 in some reactions of ocular inflammation including the breakdown of BAB and alteration of intraocular pressure.
The second messenger system for TxA2 receptors has been studied extensively.8 31 32 TxA2 acts as an agonist at a specific, G protein coupled cell surface receptor which is linked to phospholipase C. 
